Paid Clinical Trials Irving
Discover 1,702 paid clinical trials in Irving, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
AMG 509Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor:
Amgen
Location:
Code:
NCT04221542
Conditions
Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AMG 509
Abiraterone
Enzalutamide
YL202A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Sponsor:
MediLink Therapeutics (Suzhou) Co., Ltd.
Location:
Code:
NCT05653752
Conditions
Non Small Cell Lung Cancer
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
YL202
NUV-1511Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Sponsor:
Nuvation Bio Inc.
Location:
Code:
NCT06334432
Conditions
Advanced Solid Tumor
HER2-negative Breast Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pancreatic Cancer
Platinum-resistant Ovarian Cancer (PROC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NUV-1511
Radiofrequency SUIProspective US Radiofrequency SUI Trial
Sponsor:
Viveve Inc.
Location:
Code:
NCT04720352
Conditions
Urinary Incontinence, Stress
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Active treatment
Sham
IDE161A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Sponsor:
IDEAYA Biosciences
Location:
Code:
NCT05787587
Conditions
Advanced or Metastatic Solid Tumors
Breast Cancer
Ovarian Cancer
Prostate Cancer
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IDE-161
Pembrolizumab
Interested in new trials?
Get alerts for new trials in your area by subscribing now
RAS(ON) Inhibitor CombinationsStudy of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
Sponsor:
Revolution Medicines, Inc.
Location:
Code:
NCT06162221
Conditions
Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
RAS G12D-mutated NSCLC
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RMC-6291
RMC-6236
Pembrolizumab
Cisplatin
Carboplatin
PovetaciceptAn Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Sponsor:
Alpine Immune Sciences, Inc.
Location:
Code:
NCT05732402
Conditions
Lupus Nephritis
Immunoglobulin A Nephropathy
Membranous Nephropathy
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Povetacicept
Radiation TherapyProton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
Sponsor:
Massachusetts General Hospital
Location:
Code:
NCT01696721
Conditions
Pediatric Patients Treated With Radiation Therapy
Eligibility Criteria
Sex: All
Age: 0 - 21
Healthy Volunteers: Not accepted
Interventions
No intervention
IMGS-001Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Sponsor:
ImmunoGenesis
Location:
Code:
NCT06014502
Conditions
Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IMGS-001
IBI343A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Location:
Code:
NCT05458219
Conditions
Locally Advanced Unresectable or Metastatic Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IBI343